Business Context and Reporting Period
This Form 8-K filing by Sonim Technologies, Inc. (SONM) reports material events occurring on December 15 and December 16, 2025. The Company entered into a private placement and asset acquisition with DNA Holdings Venture, Inc. ("DNA Holdings") and executed a debt-for-equity exchange with Streeterville Capital, LLC. Following these transactions, the Company had 1,488,465 shares of common stock issued and outstanding.
Key Financial Metrics and Transactions
- Debt Issuance: Issued a convertible promissory note ("DNA Note") with an original principal amount of $1,200,000. The Company received $1,200,000 in cash proceeds. The note bears 10% annual interest, maturing December 15, 2026.
- Asset Acquisition: Acquired 100% of the membership interests in DNA X LLC (a DeFi trading protocol) for 223,201 shares of common stock. This issuance represented 19.99% of the Company's outstanding shares as of the issuance date.
- Debt-for-Equity Exchange: Exchanged $629,640 of principal from a prior note held by Streeterville Capital, LLC for 148,500 shares of common stock at an effective price of $4.24 per share. The remaining balance of the Streeterville note was reduced to approximately $2.3 million.
- Recent Equity Issuances: Between October and December 2025, the Company issued approximately 236,654 shares to Streeterville Capital, LLC in exchange for $810,000 of note principal.
Material Changes and Terms
- Convertible Note Terms: The DNA Note is convertible into common stock at an initial price of $5.50 per share, subject to a "full ratchet" anti-dilution adjustment if shares are issued at a lower price. The conversion price has a floor of $1.10. Upon a Change of Control, the note is redeemable at 110% of principal plus accrued interest.
- Voting Arrangements: DNA Holdings agreed to vote its shares in favor of a pending Asset Purchase Agreement with Pace Car Acquisition LLC and Social Mobile Technology Holdings LLC until January 15, 2026. DNA Holdings also received the right to designate one officer and one board nominee while holding at least 5% of the Company's stock.
- Put Option: DNA Holdings holds a put option until June 30, 2026. If DNA X fails to achieve $600 million in aggregate trading volume or $1 million in daily revenue, DNA Holdings may exchange the shares received for the DNA X membership interests.
- Covenants: The DNA Note includes negative covenants restricting additional indebtedness, liens, stock repurchases, and cash dividends while the note is outstanding.
Guidance, Risks, and Contingencies
- Financial Statement Filing: Financial statements for the acquired business (DNA X) and pro forma financial information are not included in this filing and will be submitted via amendment within 71 days.
- Performance Risk: The Put Option creates a contingency where the Company could be forced to return the DNA X assets if specific revenue or trading volume targets are not met by June 30, 2026.
- Dilution Risk: The "full ratchet" provision on the DNA Note and the issuance of shares below the Nasdaq "Minimum Price" (in the Streeterville exchange) present significant dilution risks to existing shareholders.
- Default Risk: An event of default on the DNA Note triggers an interest rate increase to 20% per annum and immediate acceleration of the debt.
Investor Verification Checklist
- Verify the financial health and trading volume metrics of DNA X LLC to assess the likelihood of the Put Option being exercised.
- Review the pending Asset Purchase Agreement with Pace Car Acquisition LLC to understand the strategic direction and potential change of control.
- Monitor the Company's ability to service the $1.2 million DNA Note and the remaining ~$2.3 million Streeterville note without violating negative covenants.
- Confirm the impact of the 1-for-18 reverse stock split (effective October 27, 2025) on historical share counts and conversion prices.
- Check for the upcoming 71-day amendment filing for DNA X's financial statements and pro forma data.